Pacira announces results from 12-month pilot study on iovera

Pacira (PCRX) BioSciences announced results from a randomized 30-patient pilot study evaluating iovera cryoneurolysis versus radiofrequency ablation, RFA, for chronic low back pain, CLBP. The study, published in Pain Physician, the official journal of the American Society of Interventional Pain Physicians, demonstrated favorable safety, pain reduction, and functional disability outcomes for patients treated with iovera degrees over a 12-month period. The iovera system is a drug-free treatment that relieves pain via cryoneurolysis, a process whereby focused cold therapy is applied to a targeted nerve, temporarily interrupting its ability to transmit pain signals. Pain relief is typically experienced immediately after treatment, with the effects lasting up to 90 days as the nerve gradually regenerates.